Home » ABGENIX TO RECEIVE MILESTONE PAYMENT FROM CHIRON FOR ADVANCEMENT OF ONCOLOGY ANTIBODY
ABGENIX TO RECEIVE MILESTONE PAYMENT FROM CHIRON FOR ADVANCEMENT OF ONCOLOGY ANTIBODY
Abgenix will receive a milestone payment from Chiron
triggered by Chiron's filing of an investigational new drug (IND) application
with the FDA for the novel oncology compound CHIR-12.12, a fully human antagonist
antibody targeting CD40. The antibody was created by Chiron using proprietary
XenoMouse technology licensed from Abgenix.
BC
Technology
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May